245 related articles for article (PubMed ID: 29589477)
1. Drug repositioning for novel antitrichomonas from known antiprotozoan drugs using hierarchical screening.
Meneses-Marcel A; Marrero-Ponce Y; Ibáñez-Escribano A; Gómez-Barrio A; Escario JA; Barigye SJ; Terán E; García-Jacas CR; Machado-Tugores Y; Nogal-Ruiz JJ; Arán-Redó VJ
Future Med Chem; 2018 Apr; 10(8):863-878. PubMed ID: 29589477
[TBL] [Abstract][Full Text] [Related]
2. Utility of antimicrobial susceptibility testing in Trichomonas vaginalis-infected women with clinical treatment failure.
Bosserman EA; Helms DJ; Mosure DJ; Secor WE; Workowski KA
Sex Transm Dis; 2011 Oct; 38(10):983-7. PubMed ID: 21934577
[TBL] [Abstract][Full Text] [Related]
3. [Treatment of urogenital trichomoniasis of both sexes with tinidazol (Fasygin)].
Rainer A
Wien Med Wochenschr; 1974 Oct; 124(42-43):625-6. PubMed ID: 4548265
[No Abstract] [Full Text] [Related]
4. [Investigation of in vitro metronidazole resistance in the clinical isolates of Trichomonas vaginalis].
Ertabaklar H; Yaman Karadam S; Malatyalı E; Ertuğ S
Mikrobiyol Bul; 2016 Oct; 50(4):552-558. PubMed ID: 28124960
[TBL] [Abstract][Full Text] [Related]
5. 5-Nitroimidazole drugs effective against metronidazole-resistant Trichomonas vaginalis and Giardia duodenalis.
Upcroft JA; Dunn LA; Wright JM; Benakli K; Upcroft P; Vanelle P
Antimicrob Agents Chemother; 2006 Jan; 50(1):344-7. PubMed ID: 16377707
[TBL] [Abstract][Full Text] [Related]
6. Strain of Trichomonas vaginalis resistant to metronidazole and other 5-nitroimidazoles.
Meingassner JG; Thurner J
Antimicrob Agents Chemother; 1979 Feb; 15(2):254-7. PubMed ID: 311617
[TBL] [Abstract][Full Text] [Related]
7. Potential of bisbenzimidazole-analogs toward metronidazole-resistant Trichomonas vaginalis isolates.
Korosh T; Bujans E; Morada M; Karaalioglu C; Vanden Eynde JJ; Mayence A; Huang TL; Yarlett N
Chem Biol Drug Des; 2017 Oct; 90(4):489-495. PubMed ID: 28296056
[TBL] [Abstract][Full Text] [Related]
8.
Ghosh AP; Aycock C; Schwebke JR
Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29439963
[TBL] [Abstract][Full Text] [Related]
9. Trichomonas vaginalis prevalence, incidence, risk factors and antibiotic-resistance in an adolescent population.
Krashin JW; Koumans EH; Bradshaw-Sydnor AC; Braxton JR; Evan Secor W; Sawyer MK; Markowitz LE
Sex Transm Dis; 2010 Jul; 37(7):440-4. PubMed ID: 20351623
[TBL] [Abstract][Full Text] [Related]
10. The genetic diversity of metronidazole susceptibility in Trichomonas vaginalis clinical isolates in an Egyptian population.
Abdel-Magied AA; El-Kholya EI; Abou El-Khair SM; Abdelmegeed ES; Hamoudaa MM; Mohamed SA; El-Tantawy NL
Parasitol Res; 2017 Nov; 116(11):3125-3130. PubMed ID: 28956167
[TBL] [Abstract][Full Text] [Related]
11. [Trichomonas vaginalis: treatment and resistance to nitroimidazoles].
Vázquez F; José García M; Pérez F; Palacio V
Enferm Infecc Microbiol Clin; 2001 Mar; 19(3):114-24. PubMed ID: 11333589
[No Abstract] [Full Text] [Related]
12. Effects of SQ109 on Trichomonas vaginalis.
de Souza TG; Granado R; Benaim G; de Souza W; Benchimol M
Exp Parasitol; 2023 Jul; 250():108549. PubMed ID: 37196704
[TBL] [Abstract][Full Text] [Related]
13. In vitro effect of octenidine dihydrochloride against Trichomonas vaginalis.
Küng E; Pietrzak J; Klaus C; Walochnik J
Int J Antimicrob Agents; 2016 Mar; 47(3):232-4. PubMed ID: 26899578
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapeutic options for the treatment of human trichomoniasis.
Küng E; Fürnkranz U; Walochnik J
Int J Antimicrob Agents; 2019 Feb; 53(2):116-127. PubMed ID: 30612993
[TBL] [Abstract][Full Text] [Related]
15. A sequential procedure for rapid and accurate identification of putative trichomonacidal agents.
Ibáñez-Escribano A; Meneses-Marcel A; Marrero-Ponce Y; Nogal-Ruiz JJ; Arán VJ; Gómez-Barrio A; Escario JA
J Microbiol Methods; 2014 Oct; 105():162-7. PubMed ID: 25107376
[TBL] [Abstract][Full Text] [Related]
16. Anti-Trichomonas vaginalis activity of ursolic acid derivative: a promising alternative.
Bitencourt FG; de Brum Vieira P; Meirelles LC; Rigo GV; da Silva EF; Gnoatto SCB; Tasca T
Parasitol Res; 2018 May; 117(5):1573-1580. PubMed ID: 29572567
[TBL] [Abstract][Full Text] [Related]
17. Novel metronidazole-chalcone conjugates with potential to counter drug resistance in Trichomonas vaginalis.
Anthwal A; Rajesh UC; Rawat MS; Kushwaha B; Maikhuri JP; Sharma VL; Gupta G; Rawat DS
Eur J Med Chem; 2014 May; 79():89-94. PubMed ID: 24727243
[TBL] [Abstract][Full Text] [Related]
18. Biological variability of Trichomonas vaginalis clinical isolates from symptomatic and asymptomatic patients.
Hussien EM; El-Sayed HZ; Shaban MM; Salm AM; Rashwan M
J Egypt Soc Parasitol; 2004 Dec; 34(3):979-88. PubMed ID: 15587322
[TBL] [Abstract][Full Text] [Related]
19. Metronidazole and Secnidazole Carbamates: Synthesis, Antiprotozoal Activity, and Molecular Dynamics Studies.
Rocha-Garduño G; Hernández-Martínez NA; Colín-Lozano B; Estrada-Soto S; Hernández-Núñez E; Prieto-Martínez FD; Medina-Franco JL; Chale-Dzul JB; Moo-Puc R; Navarrete-Vázquez G
Molecules; 2020 Feb; 25(4):. PubMed ID: 32059495
[TBL] [Abstract][Full Text] [Related]
20. Drug library screening against metronidazole-sensitive and metronidazole-resistant Trichomonas vaginalis isolates.
Goodhew EB; Secor WE
Sex Transm Infect; 2013 Sep; 89(6):479-84. PubMed ID: 23794105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
